Vernalis entered into a development and licensing deal with Tris Pharma, Inc, in February 2012, obtaining exclusive rights to Tris’ extended-release technology for use in the US prescription cough cold market with approximately 30-35 million prescriptions annually, it is potentially worth over $3 billion at 2015 brand pricing.
In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.
To see the status of these programmes at a glance – roll over any listing or click on it to find out more.
Click here for more details on Tuzistra® XR, (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III).
Click here for more details on Moxatag® and including full US Prescribing Information.